![Rafi Kazandjian](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Loopbaan van Rafi Kazandjian
Eerdere bekende functies van Rafi Kazandjian
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
Eyevensys SAS
![]() Eyevensys SAS Miscellaneous Commercial ServicesCommercial Services Eyevensys SAS develops non-viral gene therapy process for the treatment of ocular illnesses. The firm's process enables prolonged production of all therapeutic proteins through electrotransfer. Its product, the single-used device is designed for treating ocular illnesses. The company was founded by Francine Behar-Cohen on December 8, 2008 and is headquartered in Paris, France. | Directeur/Bestuurslid | 22-05-2014 | - |
Algemeen Directeur | 22-05-2014 | 12-12-2017 | |
Voorzitter | 22-05-2014 | - | |
President | 22-05-2014 | 12-12-2017 | |
Immutep SAS
![]() Immutep SAS Pharmaceuticals: MajorHealth Technology Immutep SAS specializes in biotechnology research and development. It develops immunotherapy treatments for cancer and autoimmune diseases. The company was founded by Frédéric Triebel on October 17, 2001 and is headquartered Orsay, France. | Directeur/Bestuurslid | - | 18-11-2015 |
Statistieken
Internationaal
Frankrijk | 3 |
Operationeel
Director/Board Member | 2 |
Chief Executive Officer | 1 |
Chairman | 1 |
Sectoraal
Health Technology | 2 |
Commercial Services | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Bedrijven in privébezit | 2 |
---|---|
Immutep SAS
![]() Immutep SAS Pharmaceuticals: MajorHealth Technology Immutep SAS specializes in biotechnology research and development. It develops immunotherapy treatments for cancer and autoimmune diseases. The company was founded by Frédéric Triebel on October 17, 2001 and is headquartered Orsay, France. | Health Technology |
Eyevensys SAS
![]() Eyevensys SAS Miscellaneous Commercial ServicesCommercial Services Eyevensys SAS develops non-viral gene therapy process for the treatment of ocular illnesses. The firm's process enables prolonged production of all therapeutic proteins through electrotransfer. Its product, the single-used device is designed for treating ocular illnesses. The company was founded by Francine Behar-Cohen on December 8, 2008 and is headquartered in Paris, France. | Commercial Services |
- Beurs
- Insiders
- Rafi Kazandjian
- Ervaring